Stem cells in the management of advanced heart failure

Current Opinion in Cardiology

Volumn 30, Issue 2, 2015, Pages 179-185

  Menasché, Philippe ^a  

^a PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

Author keywords

Exosomes; Heart failure; Microvesicles; Stem cells; Tissue engineering

Indexed keywords

FIREFLY LUCIFERASE; LENTIVIRUS VECTOR; LIPID; MESSENGER RNA; MICRORNA; NANOMATERIAL; POLYMER; STROMAL CELL DERIVED FACTOR 1;

ADULT STEM CELL; ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BIOLOGICAL THERAPY; CARDIAC STEM CELL; CELL COMMUNICATION; CELL DELIVERY DEVICE; CELL ORGANELLE; CLINICAL TRIAL (TOPIC); DNA MODIFICATION; DRUG DELIVERY DEVICE; EMBRYONIC STEM CELL; ENGRAFTMENT; EXOSOME; GENETIC TRANSDUCTION; HEART FAILURE; HEART MUSCLE CELL; HUMAN; MEMBRANE MICROPARTICLE; MESENCHYMAL STEM CELL; NANOVESICLE; NONHUMAN; PRIORITY JOURNAL; REVIEW; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION; TISSUE ENGINEERING;

EID: 84927780891     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0000000000000138     Document Type: Review

References (73)

1. Nowbar AN, Mielewczik M, Karavassilis M, et al., DAMASCENE Writing Group. Discrepancies in autologous bone marrow stem cell trials and enhancement of ejection fraction (DAMASCENE): weighted regression and meta-analysis. BMJ 2014; 348:2688.
2. Kandala J, Upadhyay GA, Pokushalov E, et al. Meta-analysis of stem cell therapy in chronic ischemic cardiomyopathy. Am J Cardiol 2013; 112:217- 225.
3. Menasché P, Alfieri O, Janssens S, et al. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) Trial. First randomized placebocontrolled study of myoblast transplantation. Circulation 2008; 117:1189-1200.
4. Mohsin S, Siddiqi S, Collins B, Sussman MA. Empowering adult stem cells for myocardial regeneration. Circ Res 2011; 109:1415-1428.
5. Terrovitis JV, Smith RR, Marbán E. Assessment and optimization of cell engraftment after transplantation into the heart. Circ Res 2010; 106:479- 494.
6. Iso Y, Spees JL, Serrano C, et al. Multipotent human stromal cells improve cardiac function after myocardial infarction in mice without long-term engraftment. Biochem Biophys Res Commun 2007; 354:700-706.
7. Garbern JC, Lee RT. Cardiac stem cell therapy and the promise of heart regeneration. Cell Stem Cell 2013; 12:689-698.
8. Mirotsou M, Jayawardena TM, Schmeckpeper J, et al. Paracrine mechanisms of stem cell reparative and regenerative actions in the heart. J Mol Cell Cardiol 2011; 50:280-289.
9. Loffredo FS, Steinhauser ML, Gannon J, Lee RT. Bone marrow-derived cell therapy stimulates endogenous cardiomyocyte progenitors and promotes cardiac repair. Cell Stem Cell 2011; 8:389-398.
10. Bollini S, Smart N, Riley PR. Resident cardiac progenitor cells: At the heart of regeneration. J Mol Cell Cardiol 2011; 50:296-303.
11. Senyo SE, Steinhauser ML, Pizzimenti CL, et al. Mammalian heart renewal by preexisting cardiomyocytes. Nature 2013; 493:433-436.
12. Bergmann O, Bhardwaj RD, Bernard S, et al. Evidence for cardiomyocyte renewal in humans. Science 2009; 324:98-102.
13. Li TS, Cheng K, Malliaras K, et al. Direct comparison of different stem cell types and subpopulations reveals superior paracrine potency and myocardial repair efficacy with cardiosphere-derived cells. J Am Coll Cardiol 2012; 59:942-953.
14. Oskouei BN, Lamirault G, Joseph C, et al. Increased potency of cardiac stem cells compared with bone marrow mesenchymal stem cells in cardiac repair. Stem Cells Transl Med 2012; 1:116-124.
15. Malliaras K, Makkar RR, Smith RR, et al. Intracoronary cardiosphere-derived cells after myocardial infarction: evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction). J Am Coll Cardiol 2014; 63:110-122.
16. Bartunek J, Behfar A, Dolatabadi D, et al. Cardiopoietic stem cell therapy in heart failure: The C-CURE (Cardiopoietic stem Cell therapy in heart failure) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol 2013; 61:2329-2338.
17. Cheng K, Malliaras K, Smith RR, et al. Human cardiosphere-derived cells from advanced heart failure patients exhibit augmented functional potency in myocardial repair. JACC Heart Fail 2014; 2:49-61.
18. Menasché P, Vanneaux V, Fabreguettes JR, et al. Towards a clinical use of human embryonic stem cell-derived cardiac progenitors: A translational experience. Eur Heart J 2014.
19. Blin G, Nury D, Stefanovic S, et al. A purified population of multipotent cardiovascular progenitors derived from primate pluripotent stem cells engrafts in postmyocardial infarcted nonhuman primates. J Clin Invest 2010; 120:1125-1139.
20. Burt RK, Chen YH, Verda L, et al. Mitotically inactivated embryonic stem cells can be used as an in vivo feeder layer to nurse damaged myocardium after acute myocardial infarction: A preclinical study. Circ Res 2012; 111:1286-1296.
21. Cho HJ, Lee N, Lee JY, et al. Role of host tissues for sustained humoral effects after endothelial progenitor cell transplantation into the ischemic heart. J Exp Med 2007; 204:3257-3269.
22. Levit RD, Landázuri N, Phelps EA, et al. Cellular encapsulation enhances cardiac repair. J Am Heart Assoc 2013; 2:e000367.
23. Penn MS, Pastore J, Miller T, Aras R. SDF-1 in myocardial repair. Gene Ther 2012; 19:583-587.
24. Penn MS, Mendelsohn FO, Schaer GL, et al. An open-label dose escalation study to evaluate the safety of administration of nonviral stromal cell-derived factor-1 plasmid to treat symptomatic ischemic heart failure. Circ Res 2013; 112:816-825.
25. Behfar A, Latere JP, Bartunek J, et al. Optimized delivery system achieves enhanced endomyocardial stem cell retention. Circ Cardiovasc Interv 2013; 6:710-718.
26. Penn MS, Ellis S, Gandhi S, et al. Adventitial delivery of an allogeneic bone marrow-derived adherent stem cell in acute myocardial infarction: phase I clinical study. Circ Res 2012; 110:304-311.
27. Aguado BA, Mulyasasmita W, Su J, et al. Improving viability of stem cells during syringe needle flow through the design of hydrogel cell carriers. Tissue Eng Part A 2012; 18:806-815.
28. Wang H, Zhou J, Liu Z, Wang C. Injectable cardiac tissue engineering for the treatment of myocardial infarction. J Cell Mol Med 2010; 14:1044- 1055.
29. Sekine H, Shimizu T, Dobashi I, et al. Cardiac cell sheet transplantation improves damaged heart function via superior cell survival in comparison with dissociated cell injection. Tissue Eng Part A 2011; 17:2973-2980.
30. Le-Visage C, Gournay O, Benguirat N, et al. Mesenchymal stem cell delivery into rat infarcted myocardium using a porous polysaccharide-based scaffold: A quantitative comparison with endocardial injection. Tissue Eng Part A 2012; 18:35-44.
31. Sekiya N, Tobita K, Beckman S, et al. Muscle-derived stem cell sheets support pump function and prevent cardiac arrhythmias in a model of chronic myocardial infarction. Mol Ther 2013; 21:662-669.
32. Araña M, Gavira JJ, Peña E, et al. Epicardial delivery of collagen patches with adipose-derived stem cells in rat and minipig models of chronic myocardial infarction. Biomaterials 2014; 35:143-151.
33. Hamdi H, Planat-Benard V, Bel A, et al. Epicardial adipose stem cell sheets results in greater postinfarction survival than intramyocardial injections. Cardiovasc Res 2011; 91:483-491.
34. Hamdi H, Furuta A, Bellamy V, et al. Cell delivery: intramyocardial injections or epicardial deposition? A head-to-head comparison. Ann Thorac Surg 2009; 87:1196-1203.
35. Gaballa MA, Sunkomat JN, Thai H, et al. Grafting an acellular 3-dimensional collagen scaffold onto a nontransmural infarcted myocardium induces neoangiogenesis and reduces cardiac remodeling. J Heart Lung Transplant 2006; 25:946-954.
36. Miyagi Y, Chiu LL, Cimini M, et al. Biodegradable collagen patch with covalently immobilized VEGF for myocardial repair. Biomaterials 2011; 32:1280-1290.
37. Fisher MB, Mauck RL. Tissue engineering and regenerative medicine: recent innovations and the transition to translation. Tissue Eng Part B Rev 2013; 19:1-13.
38. Cantu DA, Kao WJ. Combinatorial biomatrix/cell-based therapies for restoration of host tissue architecture and function. Adv Healthc Mater 2013; 2:1544-1563.
39. Castellano D, Blanes M, Marco BA, et al. Comparison of electrospun polymers reveals poly(3-hydroxybutyrate) fiber as a superior scaffold for cardiac repair. Stem Cells Dev 2014; 23:1479-1490.
40. Zhang H, Zhou L, Zhang W. Control of scaffold degradation in tissue engineering: A review. Tissue Eng Part B Rev 2014; 20:492-502.
41. Novosel EC, Kleinhans C, Kluger PJ. Vascularization is the key challenge in tissue engineering. Adv Drug Deliv Rev 2011; 63:300-311.
42. Sekine H, Shimizu T, Hobo K, et al. Endothelial cell coculture within tissue-engineered cardiomyocyte sheets enhances neovascularization and improves cardiac function of ischemic hearts. Circulation 2008; 118:145-152.
43. Rao C, Prodromakis T, Kolker L, et al. The effect of microgrooved culture substrates on calcium cycling of cardiac myocytes derived from human induced pluripotent stem cells. Biomaterials 2013; 34:2399-2411.
44. Feinberg AW, Alford PW, Jin H, et al. Controlling the contractile strength of engineered cardiac muscle by hierarchal tissue architecture. Biomaterials 2012; 33:5732-5741.
45. Cigognini D, Lomas A, Kumar P, et al. Engineering in vitro microenvironments for cell based therapies and drug discovery. Drug Discov Today 2013; 18:1099-1108.
46. Engler AJ, Sen S, Sweeney HL, Discher DE. Matrix elasticity directs stem cell lineage specification. Cell 2006; 126:677-689.
47. Pashuck ET, Stevens MM. Designing regenerative biomaterial therapies for the clinic. Sci Transl Med 2012; 4:160sr4.
48. Li TS, Kubo M, Ueda K, et al. Identification of risk factors related to poor angiogenic potency of bone marrow cells from different patients. Circulation 2009; 120:S255-S261.
49. Assmus B, Leistner DM, Schächinger V, et al., REPAIR-AMI Study Group. Long-term clinical outcome after intracoronary application of bone marrowderived mononuclear cells for acute myocardial infarction: Migratory capacity of administered cells determines event-free survival. Eur Heart J 2014; 35:1275-1283.
50. Ryan JM, Barry FP, Murphy JM, Mahon BP. Mesenchymal stem cells avoid allogeneic rejection. J Inflamm (Lond) 2005; 2:8.
51. Griffin MD, Ryan AE, Alagesan S, et al. Antidonor immune responses elicited by allogeneic mesenchymal stem cells: what have we learned so far? Immunol Cell Biol 2013; 91:40-51.
52. Suncion VY, Ghersin E, Fishman JE, et al. Does transendocardial injection of mesenchymal stem cells improve myocardial function locally or globally?: An analysis from the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis (POSEIDON) randomized trial. Circ Res 2014; 114:1292-1301.
53. Kuo YR, Chen CC, Goto S, et al. Immunomodulatory effects of bone marrowderived mesenchymal stem cells in a swine hemi-facial allotransplantation model. PLoS One 2012; 7:e35459.
54. Tan J, Wu W, Xu X, et al. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: A randomized controlled trial. JAMA 2012; 307:1169-1177.
55. Gajanayake T, Olariu R, Leclère F, et al. A single localized dose of enzymeresponsive hydrogel improves long-term survival of a vascularized composite allograft. Sci Transl Med 2014; 6:249ra110.
56. De-Almeida PE, Ransohoff JD, Nahid A, Wu JC. Immunogenicity of pluripotent stem cells and their derivatives. Circ Res 2013; 112:549-561.
57. Timmers L, Lim SK, Hoefer IE, et al. Human mesenchymal stem cell-conditioned medium improves cardiac function following myocardial infarction. Stem Cell Res 2011; 6:206-214.
58. Fidelis-de-Oliveira P, Werneck-de-Castro JP, Pinho-Ribeiro V, et al. Soluble factors from multipotent mesenchymal stromal cells have antinecrotic effect on cardiomyocytes in vitro and improve cardiac function in infarcted rat hearts. Cell Transplant 2012; 21:1011-1021.
59. Yuan A, Farber EL, Rapoport AL, et al. Transfer of microRNAs by embryonic stem cell microvesicles. PLoS One 2009; 4:e4722.
60. Vlassov AV, Magdaleno S, Setterquist R, Conrad R. Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. Biochim Biophys Acta 2012; 1820:940-948.
61. Porrello ER. MicroRNAs in cardiac development and regeneration. Clin Sci (Lond) 2013; 125:151-166.
62. Dai Y, Khaidakov M, Wang X, et al. MicroRNAs involved in the regulation of postischemic cardiac fibrosis. Hypertension 2013; 61:751-756.
63. Biancone L, Bruno S, Deregibus MC, et al. Therapeutic potential of mesenchymal stem cell-derived microvesicles. Nephrol Dial Transplant 2012; 27:3037-3042.
64. Bruno S, Grange C, Deregibus MC, et al. Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. J Am Soc Nephrol 2009; 20:1053-1067.
65. Barile L, Lionetti V, Cervio E, et al. Extracellular vesicles from human cardiac progenitor cells inhibit cardiomyocyte apoptosis and improve cardiac function after myocardial infarction. Cardiovasc Res 2014; 103:530-541.
66. Lai RC, Arslan F, Lee MM, et al. Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res 2010; 4:214-222.
67. Ibrahim AG, Cheng K, Marbán E. Exosomes as critical agents of cardiac regeneration triggered by cell therapy. Stem Cell Rep 2014; 2:606- 619.
68. Zhang HC, Liu XB, Huang S, et al.Microvesicles derived from human umbilical cord mesenchymal stem cells stimulated by hypoxia promote angiogenesis both in vitro and in vivo. Stem Cells Dev 2012; 21:3289-3297.
69. Lakhal S, Wood MJ. Exosome nanotechnology: An emerging paradigm shift in drug delivery: exploitation of exosome nanovesicles for systemic in vivo delivery of RNAi heralds new horizons for drug delivery across biological barriers. Bioessays 2011; 33:737-741.
70. Ratajczak J, Miekus K, Kucia M, et al. Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia 2006; 20:847-856.
71. Waldenström A, Gennebäck N, Hellman U, Ronquist G. Cardiomyocyte microvesicles contain DNA/RNA and convey biological messages to target cells. PLoS One 2012; 7:e34653.
72. Graf T. Historical origins of transdifferentiation and reprogramming. Cell Stem Cell 2011; 9:504-516.
73. Segers VF, Lee RT. Protein therapeutics for cardiac regeneration after myocardial infarction. J Cardiovasc Transl Res 2010; 3:469-477.